Neurocrine Biosciences | NBIX - 股本和储备



金融业
股票价格
USD
资产
USD 5.36B
现金及等价物
USD 332.4M
销售成本
USD 39.4M
流动资产
USD 1.64B
流动负债
USD 874.5M
债务
USD 406.2M
EBIT
USD 219.9M
EBITDA
USD 193.3M
员工
1.8K
EPS每股收益
USD 2.85
股本和储备
USD 3.69B
销售毛利
USD 800.7M
债务利息支出
USD 1.1M
贷款资金
USD 169.5M
市值
USD 15.76B
净收入
USD 144.4M
营业费用
USD 739.1M
营业利润
USD 219.9M
普通股股本
USD 100.55M
PE价格收益
22.1
税前利润
USD 246.8M
销售收入
USD 959M
销售和管理费用
USD 383.1M
股票
USD 104.2M
贸易债权人
USD 691.3M
应收帐款人
USD 887M


股本和储备 更改 日
AbbVie USD -5.94B 721M 2026-06
Acadia Pharmaceuticals USD 1.31B 58.54M 2026-06
Agios Pharmaceuticals USD 1.03B 83.09M 2026-06
ALKERMES USD 1.81B 57.02M 2026-06
Alnylam Pharmaceuticals USD 1.35B 278.74M 2026-06
Amgen USD 11.69B 2.5B 2026-06
Biogen USD 18.85B 196.3M 2026-06
BioMarin Pharmaceutical USD 6.32B 109.58M 2026-06
Cytokinetics USD -173.49M 653.08M 2026-06
Enanta Pharmaceuticals USD 126.59M 61.87M 2025-12
Exelixis USD 1.84B 91.99M 2026-06
Gilead Sciences USD 11.74B 11.77B 2026-06
Halozyme Therapeutics USD 143.54M 76.09M 2026-06
Incyte USD 6.34B 721.58M 2026-06
Ionis Pharmaceuticals USD 439.74M 51.68M 2026-06
Nektar Therapeutics USD 576.22M 486.38M 2026-03
Neurocrine Biosciences USD 3.69B 286.2M 2026-06
Pfizer USD 85.19B 4.91B 2026-06
Prothena USD 286.89M 25.72M 2026-06
Regeneron Pharmaceuticals USD 31.71B 287.8M 2026-06
Repligen USD 2.11B 6.57M 2026-06
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sarepta Therapeutics USD 1.53B 22.7M 2026-06
Teva Pharmaceutical Industries USD 7.75B 475M 2026-06
Ultragenyx Pharmaceutical USD -291M 55M 2026-06
Vertex Pharmaceuticals USD 20.25B 886M 2026-06